ESI National Preferred Formulary Exclusion Changes

What is the value of managing drug trend across both the pharmacy and medical benefit?

Opportunity Offered by a Good Crisis: COVID-19 IMPACT ON INNOVATIVE PRICING MODELS

Drug Coverage in the Pandemic: US Payers Shift Focus From Costs To Access, For Now

Market Access 2020: Understanding US Payer Expectations

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Examining New Payment Ideas for Curative Therapies

AstraZeneca strikes a ‘novel’ deal with Medicare plan to lower patient out-of-pocket costs

What rebates? Express Scripts touts a new plan to appease critics of the opaque drug-pricing system